Of course that happens but keep in mind that many company do this management and insider enrichment which includes high compensation for promises of increasing investor value, often unfulfilled. Often it appears that the greater the company losses the greater the compensation. Elite's management should be compensated for results and not fluff or better yet a reasonable compensation package should be set for management according to competitive recruitment and not on how is buddy with whom. There should be a build in clause in contract to reduce compensation for company losses just as there for company income and revenues. The only redeeming situation about Elite is that all the shares that the issue are none dilutive. Need a link? Might not be worth the paper its written in just as some paid or compensated commentary.
Must add that Elite's problems are a combo of self created issues and competition in the market place. FDA delays should not be factor in heavily because Elite's management is well compensated to take this into account in planning and minimizing management problems, i.e., API fiasco that in all likely caused Elite big money. Finally all shares is dilutive no matter what the purpose of issue.
Market Data 
Markets 
AI
